Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

Дата публикации: 25-06-2026 00:00:00

This cohort study explores the long-term outcomes of patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026
2	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
3	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
4	Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma	5	7	30-06-2026
5	Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy	0	7	18-06-2026
6	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
7	Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence Over Tamoxifen and Further Reduction Is Seen When Combined with Exemestane	0	5	06-07-2026
8	Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	0	7	25-06-2026
9	Survival in the SONIA Trial	0	8	18-06-2026
10	Апоплексия яичника: оценка региональных особенностей, факторов риска и современных подходов к органосохраняющему лечению	0	7	16-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.